Clinical Trial Update: Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) "After Multiple Oral Doses" in Healthy Volunteers [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated safety, tolerability, and pharmacokinetics of PBF-509 at 80 mg, 160 mg, and 240 mg after multiple oral doses in healthy volunteers …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• PBF-509

Snippet

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED